Astellas Pharma (TSE:4503) Margin Surge To 13.6% Tests Bearish Earnings Narratives

Astellas Pharma (TSE:4503) has laid out its FY 2026 scorecard with second half revenue of ¥1.1t and basic EPS of ¥80.33, alongside net income excluding extraordinary items of ¥143.9b. The company has seen revenue move from ¥976.7b and basic EPS of ¥12.72 in the second half of FY 2025, to ¥1.0t and ¥82.44 in the first half of FY 2026, before reaching ¥1.1t and ¥80.33 in the latest period. Over the same timeframe, trailing twelve month EPS has increased from ¥28.35 to ¥162.77. For investors, the headline here is an earnings profile backed by higher net profit margins over the last year, which invites a closer look at how sustainable this profitability mix may be.

See our full analysis for Astellas Pharma.

With the latest figures on the table, the next step is to compare these margins and earnings trends with the most common market narratives around Astellas Pharma and assess which stories still appear well supported and which may be becoming outdated.

See what the community is saying about Astellas Pharma

Margins Stretch Out To 13.6%

• On a trailing twelve month basis, Astellas converted ¥2.1t of revenue into ¥291.5b of net income excluding extraordinary items, which works out to a 13.6% net margin compared with 2.7% a year earlier.
• Bullish investors point to the fact that this higher 13.6% margin sits alongside very large reported earnings growth over the past year. At the same time, the bullish narrative assumes margins ease back from 15.7% to 12.5% by around 2029. The current profitability level therefore gives them evidence of earnings power while also raising the question of how much of this margin profile can realistically be carried forward.

Over the last 12 months, reported earnings grew roughly 6x.

• Trailing twelve month basic EPS moved from ¥28.35 at the end of the prior year period to ¥162.77 at the latest reading, a change that aligns with the cited 474.5% earnings growth rate.
• For the bullish narrative, this kind of jump in EPS and net income supports the view that faster cost reductions and R&D efficiencies are already feeding through to profit. Even so, the optimistic camp is modeling earnings of ¥253.9b and EPS of ¥141.8 by 2029, which is lower than the ¥322.9b reference point cited for today. Anyone leaning bullish therefore needs to reconcile this strong recent EPS with the fact that analysts, including bullish ones, still frame the medium term as earnings contraction rather than simple straight line growth.

🐂 Astellas Pharma Bull Case

Cheap P/E And DCF Gap

• The shares change hands at ¥2,291.50 with a trailing P/E of 14.1x, compared with a peer average P/E of 29.9x and a JP Pharmaceuticals industry average P/E of 15.5x. The price also sits well below a DCF fair value of ¥4,580.24.
• Critics highlight that even with this discount, analysts expect earnings to decline by about 11.2% per year over the next three years and revenue to fall roughly 6.2% per year. This means the low P/E and gap to DCF fair value can be read either as an opportunity if you think the modeled earnings slide is too harsh, or as a signal that the market is already factoring in those weaker forward numbers.

Bear Case Focuses On Shrinking Top Line

• Across the last three semi annual points, revenue progressed from ¥976,702m in the second half of FY 2025 to ¥1,030,114m in the first half of FY 2026 and ¥1,109,131m in the second half. Analyst models referenced in the cautious view nonetheless call for annual revenue declines of around 5.4% in the bearish case and 3.5% in the consensus case over the coming years.
• Bears argue that patent expiries on key products and pressure on drug pricing will make it hard to replace revenue. That is reflected in their scenario where revenue is assumed to fall to ¥1,648.6b and earnings to ¥118.0b by about 2028, so the current trailing twelve month net income of ¥291.5b and 13.6% margin are being weighed directly against those projected lower revenue and earnings figures when cautious investors assess how exposed the business might be to loss of exclusivity and policy changes.

🐻 Astellas Pharma Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Astellas Pharma on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.

With the mix of optimism and concern around Astellas Pharma, it helps to move quickly and look at the details yourself to see what stands out. To weigh both sides of the story, review the 4 key rewards and 1 important warning sign

See What Else Is Out There

Analysts are modeling annual revenue and earnings declines for Astellas Pharma, which raises questions about how durable the current earnings and margin profile really is for long term holders.

If shrinking revenue potential worries you, it makes sense to compare this setup with companies screened for resilient performance and lower downside risk using the 46 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com